Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2015

01-04-2015 | Research Article

Association between polymorphisms of microRNA-binding sites in integrin genes and gastric cancer in Chinese Han population

Authors: Xingbo Song, Huiyu Zhong, Juan Zhou, Xuejiao Hu, Yi Zhou, Yuanxin Ye, Xiaojun Lu, Jun Wang, Binwu Ying, Lanlan Wang

Published in: Tumor Biology | Issue 4/2015

Login to get access

Abstract

Highly elevated expression of integrin has been observed in a variety of malignant tumors. Single nucleotide polymorphisms (SNPs) in the microRNA-binding sites in the 3′ UTR region of target genes may result in the level change of target gene expression and subsequently susceptible to diseases, including cancer. In this study, we aimed to investigate the association between polymorphisms of microRNA-binding sites of integrin genes and gastric cancer (GC) in Chinese Han population. Five SNPs of the microRNA-binding sites in the 3′ UTR region of integrin genes (rs1062484 C/T in ITGA3, rs17664 A/G in ITGA6, rs3809865 A/T in ITGB3, rs743554 C/T in ITGB4, and rs2675 A/C in ITGB5) were studied using high resolution melting (HRM) analysis in 1000 GC patients and 1000 unrelated controls. The polymorphism of SNP rs2675 was associated with susceptibility of GC [odds ratio (OR) = 0.52, 95 % confidence interval (CI) = 0.28–0.97, P = 0.028]. In addition, genotype AA of rs2675 and genotype GG of rs17664 were associated with a lower chance of GC at stage 1b [OR = 0.39 (0.18–0.85), P = 0.009; and OR = 0.37 (0.17–0.78), P = 0.004, respectively]; also, the frequency of allele G of rs17664 was associated with a lower chance of stage 1b tumor [OR = 0.50 (0.26–0.95), P = 0.021]. Furthermore, the frequency of genotype AA and allele A of rs3809865 were associated with a higher risk of stage 4 GC [OR = 1.85 (1.11–3.09), P = 0.012; and OR = 1.52 (0.99–2.33), P = 0.043, respectively]. For rs17664, GG genotype and allele G appeared to be associated with a higher risk with GC with lymphatic metastasis 3b [OR = 1.76 (1.00–3.11), P = 0.036; and OR = 1.64 (0.98–2.75), P = 0.048, respectively]. Our data suggest that polymorphisms of the microRNA-binding sites in the 3′ UTR region of integrin are associated with GC susceptibility (rs2675), tumor stage (rs2675, rs17664, and rs3809865), and lymphatic metastasis (rs17664) in Chinese Han population.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Coupland VH, Lagergren J, Lüchtenborg M, Jack RH, Allum W, Holmberg L, et al. Hospital volume, proportion resected and mortality from oesophageal and gastric cancer: a population-based study in England, 2004–2008. Gut. 2013;62:961–6.CrossRefPubMed
3.
Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. J Surg Oncol. 2013;107:230–6.CrossRefPubMed
4.
Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17:3077–9.CrossRefPubMed
5.
Pan Y, Bi F, Liu N, Xue Y, Yao X, Zheng Y, et al. Expression of seven main Rho family members in gastric carcinoma. Biochem Biophys Res Commun. 2004;315:686–91.CrossRefPubMed
6.
Stadtländer CT, Waterbor JW. Molecular epidemiology, pathogenesis and prevention of gastric cancer. Carcinogenesis. 1999;20:2195–208.CrossRefPubMed
7.
8.
9.
Lu F, Xue JX, Hu YC, Gan L, Shi Y, Yang HS, et al. CARP is a potential tumor suppressor in gastric carcinoma and a single-nucleotide polymorphism in CARP genemight increase the risk of gastric carcinoma. PLoS One. 2014;9:e97743.CrossRefPubMedPubMedCentral
10.
Wang M, Li C, Nie H, Lv X, Qu Y, Yu B, et al. Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK. FEBS Lett. 2012;586:2382–8.CrossRefPubMed
11.
Palmero EI, de Campos SG, Campos M, de Souza NC, Guerreiro ID, Carvalho AL, et al. Mechanisms and role of microRNA deregulation in cancer onset and progression. Genet Mol Biol. 2011;34:363–70.CrossRefPubMedPubMedCentral
12.
13.
Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006;25:6188–96.CrossRefPubMed
14.
Mouw JK, Yui Y, Damiano L, Bainer RO, Lakins JN, Acerbi I. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. Nat Med. 2014;20:360–7.CrossRefPubMedPubMedCentral
15.
16.
Tanentzapf G, Brown NH. An interaction between integrin and the talin FERM domain mediates integrin activation but not linkage to the cytoskeleton. Nat Cell Biol. 2006;8:601–6.CrossRefPubMed
17.
Bökel C, Brown NH. Integrins in development: moving on, responding to, and sticking to the extracellular matrix. Dev Cell. 2002;3:311–21.CrossRefPubMed
18.
Ye P, Li Z, Jiang H, Liu T. SNPs in microRNA-binding sites in the ITGB1 and ITGB3 3′ UTR increase colorectal cancer risk. Cell Biochem Biophys. 2014;70:601–7.CrossRefPubMed
19.
Liu J, Huang J, He Y, Liu J, Liao B, Liao G. Genetic variants in the integrin gene predicted microRNA-binding sites were associated with the risk of prostate cancer. Mol Carcinog. 2014;53:280–5.CrossRefPubMed
20.
Brendle A, Lei H, Brandt A, Johansson R, Enquist K, Henriksson R, et al. Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. Carcinogenesis. 2008;29:1394–9.CrossRefPubMed
21.
Chen J, Liu NN, Li JQ, Yang L, Zeng Y, Zhao XM, et al. Association between ITGA2 C807T polymorphism and gastric cancer risk. World J Gastroenterol. 2011;17:2860–6.PubMedPubMedCentral
22.
Scartozzi M, Loretelli C, Bearzi I, Mandolesi A, Galizia E, Onofri A, et al. Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. Ann Oncol. 2011;22:897–902.CrossRefPubMed
23.
24.
Mavrakis KJ, Wolfe AL, Oricchio E, Palomero T, de Keersmaecker K, McJunkin K, et al. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol. 2010;12:372–9.CrossRefPubMedPubMedCentral
25.
Segura MF, Belitskaya-Lévy I, Rose AE, Zakrzewski J, Gaziel A, Hanniford D, et al. Melanoma microRNA signature predicts post-recurrence survival. Clin Cancer Res. 2010;16:1577–86.CrossRefPubMedPubMedCentral
26.
Ahn DH, Rah H, Choi YK, Jeon YJ, Min KT, Kwack K, et al. Association of the miR-146aC>G, miR-149T>C, miR-196a2T>C, and miR-499A>G polymorphisms with gastric cancer risk and survival in the Korean population. Mol Carcinog. 2013;52:39–51.CrossRef
27.
Georges M, Coppieters W, Charlie C. Polymorphic miRNA-mediated gene regulation: contribution to phenotypic variation and disease. Curr Opin Genet Dev. 2007;17:166–76.CrossRefPubMed
28.
Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, et al. Genetic variants in microRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res. 2010;70:9765–76.CrossRefPubMedPubMedCentral
29.
Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M, et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res. 2010;70:2789–98.CrossRefPubMedPubMedCentral
30.
Wynendaele J, Böhnke A, Leucci E, Nielsen SJ, Lambertz I, Hammer S, et al. An illegitimate microRNA target site within the 3′ UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res. 2010;70:9641–9.CrossRefPubMed
31.
Xu Y, Ma H, Yu H, Liu Z, Wang LE, Tan D, et al. The miR-184 binding-site rs8126 T>C polymorphism in TNFAIP2 is associated with risk of gastric cancer. PLoS ONE. 2013;8:e64973.CrossRefPubMedPubMedCentral
32.
Paszek MJ, DuFort CC, Rossier O, Bainer R, Mouw JK, Godula K, et al. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature. 2014;511:319–25.CrossRefPubMedPubMedCentral
33.
Dutta A, Li J, Lu H, Akech J, Pratap J, Wang T, et al. Integrin αvβ6 promotes an osteolytic program in cancer cells by upregulating MMP2. Cancer Res. 2014;74:1598–608.CrossRefPubMedPubMedCentral
34.
Lee C, Lee C, Lee S, Siu A, Ramos DM. The cytoplasmic extension of the integrin β6 subunit regulates epithelial-to-mesenchymal transition. Anticancer Res. 2014;34:659–64.PubMed
35.
Pocheć E, Janik M, Hoja-Łukowicz D, Link-Lenczowski P, Przybyło M, Lityńska A. Expression of integrins α3β1 and α5β1 and GIcNAc β1,6 glycan branching influences metastatic melanoma cell migration on fibronectin. Eur J Cell Biol. 2013;92:355–62.CrossRefPubMed
36.
Saito Y, Sekine W, Sano R, Komatsu S, Mizuno H, Katabami K, et al. Potentiation of cell invasion and matrix metalloproteinase production by alpha3beta1 integrin-mediated adhesion of gastric carcinoma cells to laminin-5. Clin Exp Metastasis. 2010;27:197–205.CrossRefPubMed
37.
Pawelek JM, Chakraborty AK. The cancer cell–leukocyte fusion theory of metastasis. Adv Cancer Res. 2008;101:397–444.CrossRefPubMed
38.
Chen W, Harbeck MC, Zhang W, Jacobson JR. MicroRNA regulation of integrins. Transl Res. 2013;162:133–43.CrossRefPubMed
39.
Wang Y, Long L, Li T, Zhou Y, Jiang L, Zeng X, et al. Polymorphisms of microRNA-binding sites in integrin genes are associated with oral squamous cell carcinoma susceptibility and progression. Tohoku J Exp Med. 2014;233:33–41.CrossRefPubMed
40.
Ma XR, Cheng H, Wang XY, Liu H, Zhao D. Single-nucleotide polymorphisms of integrins are associated with the risk and lymph node metastasis of oral squamous cell carcinoma. Med Oncol. 2012;29:2492–8.CrossRefPubMed
41.
Zhang Y, Han Y, Dong L, Yu H, Cheng L, Zhao X, et al. Genetic variation of ITGB3 is associated with asthma in Chinese Han children. PLoS One. 2013;8:e56914.CrossRefPubMedPubMedCentral
42.
Ma DQ, Rabionet R, Konidari I, Jaworski J, Cukier HN, Wright HH, et al. Association and gene-gene interaction of SLC6A4 and ITGB3 in autism. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:477–83.PubMed
43.
Azimzadeh P, Romani S, Mohebbi SR, Mahmoudi T, Vahedi M, Fatemi SR, et al. Association of polymorphisms in microRNA-binding sites and colorectal cancer in an Iranian population. Cancer Genet. 2012;205:501–7.CrossRefPubMed
44.
Li ZH, Pan XM, Han BW, Guo XM, Zhang Z, Jia J, et al. A let-7 binding site polymorphism rs712 in the KRAS 3′ UTR is associated with an increased risk of gastric cancer. Tumour Biol. 2013;34:3159–63.CrossRefPubMed
45.
Lin Y, Nie Y, Zhao J, Chen X, Ye M, Li Y, et al. Genetic polymorphism at miR-181a binding site contributes to gastric cancer susceptibility. Carcinogenesis. 2012;33:2377–83.CrossRefPubMed
46.
Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91–100.CrossRefPubMed
47.
Kumar CC. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets. 2003;4:123–31.CrossRefPubMed
48.
Lamb LE, Zarif JC, Miranti CK. The androgen receptor induces integrin α6β1 to promote prostate tumor cell survival via NF-κB and Bcl-xL independently of PI3K signaling. Cancer Res. 2011;71:2739–49.CrossRefPubMed
49.
Cordes N, Park CC. beta1 integrin as a molecular therapeutic target. Int J Radiat Biol. 2007;83:753–60.CrossRefPubMed
Metadata
Title
Association between polymorphisms of microRNA-binding sites in integrin genes and gastric cancer in Chinese Han population
Authors
Xingbo Song
Huiyu Zhong
Juan Zhou
Xuejiao Hu
Yi Zhou
Yuanxin Ye
Xiaojun Lu
Jun Wang
Binwu Ying
Lanlan Wang
Publication date
01-04-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2903-z

Other articles of this Issue 4/2015

Tumor Biology 4/2015 Go to the issue

Research Article

Cyr61 promotes growth of glioblastoma in vitro and in vivo

Research Article

Inhibition of prostatic cancer growth by ginsenoside Rh2

Research Article

Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer

Research Article

Overexpression of miR-200a suppresses epithelial-mesenchymal transition of liver cancer stem cells

Research Article

Inhibition of metastasis of oral squamous cell carcinoma by anti-PLGF treatment

Research Article

Induction of S phase arrest and apoptosis by ethyl acetate extract from Tetrastigma hemsleyanum in human hepatoma HepG2 cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits